Currently out of the existing stock ratings of Ami Fadia, 499 are a BUY (89.91%), 51 are a HOLD (9.19%), 5 are a SELL (0.9%).

Ami Fadia

Work Performance Price Targets & Ratings Chart

Analyst Ami Fadia, currently employed at NEEDHAM, carries an average stock price target met ratio of 52.02% that have a potential upside of 39.79% achieved within 179 days.

Ami Fadia’s has documented 1,055 price targets and ratings displayed on 41 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on RVMD, Revolution Medicines at 31-Aug-2026.

Wall Street Analyst Ami Fadia

Analyst best performing recommendations are on PRAX (PRAXIS PRECISION MEDICINES ).
The best stock recommendation documented was for RVMD (REVOLUTION MEDICINES) at 10/12/2023. The price target of $34 was fulfilled within 4 days with a profit of $9.8 (40.5%) receiving and performance score of 101.24.

Average potential price target upside

of $77.12 (62.51%) on JAZZ (JAZZ PHARMACEUTICALS PLC).
of $66.82 (111.26%) on PRAX (PRAXIS PRECISION MEDICINES ).
of $59.74 (27.07%) on BIIB (BIOGEN).

AMRN Amarin PLC ARDX Ardelyx AVDL Avadel Pharmaceuticals PLC BIIB Biogen HRMY Harmony Biosciences Holdings HRTX Heron Therapeuti JAZZ Jazz Pharmaceuticals PLC MYOV Myovant Sciences Ltd OBSV ObsEva SA SAGE Sage Therapeutic BCYC Bicycle Therapeutics Ltd ITCI Intracellular Th MNK Mallinckrodt plc MRUS Merus BV NBIX Neurocrine Biosciences TEVA Teva Pharma Industries Ltd ADR ACAD ACADIA Pharmaceuticals AMRX Amneal Pharmaceuticals, Common Stock MYL Viatris PCRX Pacira Pharmaceuticals SGEN Seagen VTRS Viatris DAWN Day One Biopharmaceuticals ASRT Assertio Therapeutics BPMC Blueprint Medicines Corp COGT Cogent Biosciences ENDP Endo International PLC PRGO Perrigo Company PLC RVMD Revolution Medicines THRX Theseus Pharmaceuticals IMRX Immuneering Corp AXSM Axsome Therapeutics PRAX Praxis Precision Medicines NMRA Neumora Therapeutics ALKS Alkermes Plc OSMT Osmotica Pharmaceuticals plc RVLP RVL Pharmaceuticals PLC GHRS GH Research PLC ATAI ATAI Life Sciences BV AVD American Vanguard IT Gartner

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Roanna Ruiz (LEERINK)

Hold Since 19-Oct-2022

$12

$-3.91 (-24.58%)

$800

10 months 15 days ago
(30-Oct-2025)

2/4 (50%)

$-4.4 (-26.83%)

1055

Please subscribe to see extended stock data

Louise Chen (CANTOR FITZGERALD)

Buy Since 16-Apr-2021

2 years 2 months 25 days ago
(20-Jun-2024)

12/26 (46.15%)

$-53.8 (-84.33%)

1398

Please subscribe to see extended stock data

Jessica Fye (JPMORGAN)

Sell Since 06-May-2022

2 years 9 months 25 days ago
(20-Nov-2023)

0/2 (0%)

$1519.2 (1880.20%)

Please subscribe to see extended stock data

Michael Yee (JEFFERIES)

Buy Since 25-Oct-2023

$20

$5.52 (38.12%)

2 years 10 months 20 days ago
(25-Oct-2023)

1/17 (5.88%)

$5.8 (40.85%)

Please subscribe to see extended stock data

Carl Byrnes (NORTHLAND CAPITAL MARKETS)

Hold Since 19-Jul-2023

$25

$10.52 (72.65%)

3 years 1 months 26 days ago
(19-Jul-2023)

1/2 (50%)

$3.4 (15.74%)

175

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Ami Fadia most bullish on?

Potential upside of $247.42 has been obtained for PRAX (PRAXIS PRECISION MEDICINES )

Which stock is Ami Fadia most reserved on?

Potential downside of -$0 has been obtained for ATAI (ATAI LIFE SCIENCES BV)

What Year was the first public recommendation made by Ami Fadia?

On 2016